Moolec Science CTO reports initial option holdings

Moolec Science SA filed an initial insider holdings report for Chief Technology Officer Paola Alexandra Diaz Dellavalle.

Accepted by SEC EDGAR 03/18/2026 - 06:35 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Moolec Science SA filed an initial insider holdings report for Chief Technology Officer Paola Alexandra Diaz Dellavalle. She holds share options over 934 ordinary shares at an exercise price of 7.1400 per share expiring on June 30, 2031, and additional options over 933 shares each expiring on June 30, 2032 and June 30, 2033. These entries reflect her option-based equity position rather than new share purchases or sales.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Diaz Dellavalle Paola Alexandra

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Holding	Ordinary shares	--	--	--
Holding	Ordinary shares	--	--	--
Holding	Ordinary shares	--	--	--

Holdings: Ordinary shares — 2,800 contracts (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Moolec Science (MLEC) CTO report in this Form 3 filing?

The filing shows Moolec Science’s CTO, Paola Alexandra Diaz Dellavalle, reporting her initial equity position through stock options. It lists option grants over ordinary shares, including exercise price, number of underlying shares, and long-dated expiration schedules extending to 2033.

How many Moolec Science (MLEC) shares underlie the CTO’s reported options?

The CTO’s option holdings cover 934 underlying ordinary shares in one grant and 933 underlying ordinary shares in each of two additional grants. These option positions indicate potential future share ownership if she chooses to exercise them.

What is the exercise price of the Moolec Science (MLEC) CTO’s options?

All reported option grants for the CTO have an exercise price of 7.1400 per ordinary share. This is the price she would pay per share if she exercises the options, separate from the market price at the time of exercise.

When do the Moolec Science (MLEC) CTO’s options expire?

The CTO’s options expire on three different dates: June 30, 2031, June 30, 2032, and June 30, 2033. These staggered expirations suggest multiple grants, each with its own long-term time frame for potential exercise.

Does this Moolec Science (MLEC) Form 3 show the CTO buying or selling shares?

The report does not show the CTO buying or selling shares. It records existing option-based holdings over ordinary shares, detailing the number of underlying shares, exercise price, and expiration dates, rather than any new market transactions or disposals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Diaz Dellavalle Paola Alexandra

(Last) (First) (Middle)

FRANCISCO DE MEDINA 1474

(Street)

MONTEVIDEO MONTEVIDEO 11600

(City) (State) (Zip)

URUGUAY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
02/06/2026

3. Issuer Name and Ticker or Trading Symbol
Moolec Science SA [ MLEC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Ordinary shares	02/06/2026	06/30/2031	Share Option	934	$7.14	D
Ordinary shares	06/30/2027	06/30/2032	Share Option	933	$7.14	D
Ordinary shares	06/30/2028	06/30/2033	Share Option	933	$7.14	D

Explanation of Responses:

	/s/ Paola Alexandra Diaz Dellavalle	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)